Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

What is new in the 2024 Chinese guidelines for fatty liver disease?

Rui-Xu Yang, Vincent Wai-Sun Wong, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(3):e239-e246. Published online January 21, 2025

DOI: https://doi.org/10.3350/cmh.2024.1165

View: 934 Download: 69

Reply to Correspondence

Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Jing Zeng, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(2):e218-e220. Published online February 3, 2025

DOI: https://doi.org/10.3350/cmh.2025.0070

View: 902 Download: 29

Editorial

A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Jing Zeng, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(2):610-614. Published online December 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.1099

View: 1175 Download: 43 Web of Science: 2 Crossref: 2

Reply to Correspondence

Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”

Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan

Clin Mol Hepatol. 2024;30(4):1039-1041. Published online September 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0801

View: 1416 Download: 34

Editorial

Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis”

Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan

Clin Mol Hepatol. 2024;30(4):649-652. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0558

View: 2593 Download: 106 Web of Science: 3 Crossref: 2

Review

Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis

Yi-wen Shi, Jian-Gao Fan

Clin Mol Hepatol. 2023;29(Suppl):S228-S243. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0401

View: 5381 Download: 127 Web of Science: 4 Crossref: 4

Editorial

Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?

Qian Jin, Rui-Xu Yang, Jian-Gao Fan

Clin Mol Hepatol. 2022;28(3):473-477. Published online June 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0155

View: 5085 Download: 112 Web of Science: 2 Crossref: 2

Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try

Tian-Yi Ren, Xiao-Yan Li, Jian-Gao Fan

Clin Mol Hepatol. 2021;27(1):83-86. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0298

View: 6353 Download: 172 Web of Science: 2 Crossref: 4

1 |

Viewed By 12753	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7683	Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Viewed By 7187	MAFLD: How is it different from NAFLD?
Viewed By 5739	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5681	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 369	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 354	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 232	MAFLD: How is it different from NAFLD?
Cited By 122	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 116	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search